Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.46 |
| ▸ | HTR2A | P28223 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PNLIP | P16233 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812244 | 0.82 | MAOB (0.47) | SLC6A4HTR2AKCNH2F2F10 | |
| SCHEMBL13860118 | 0.81 | HSPB1 (0.42) | SLC6A4HTR2AKCNH2APPHSPB1 | |
| SCHEMBL4372913 | 0.78 | HSPB1 (0.58) | SLC6A4HTR2AKCNH2APPHSPB1 | |
| SCHEMBL2814306 | 0.76 | HSPB1 (0.68) | HSPB1LMNA | |
| SCHEMBL9338779 | 0.75 | HTR2A (0.39) | SLC6A4HTR2AKCNH2HSPB1F2 | |
| SCHEMBL1028659 | 0.75 | HTR2A (0.47) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL16695420 | 0.75 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2HSPB1F2 | |
| SCHEMBL1028660 | 0.75 | ESR1 (0.44) | SLC6A4HTR2AKCNH2F2F10 | |
| SCHEMBL365087 | 0.74 | APP (0.57) | KCNH2APPHSPB1LMNA | |
| SCHEMBL2808333 | 0.71 | LPL (0.51) | SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249192-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2010-09-30 | — | — | US | disclosed |
| EP-2231649-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009073973-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249192-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | SLC6A4 4693/4885HTR2A 2812/4885KCNH2 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.